Topic: Blood-brain barrier
Paul-Peter Tak joins Kintai Therapeutics as it steers its “precision enteric medicines” toward the clinic, with the first trials slated to start in 2020.
Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.
The partners will work to develop adeno-associated virus vectors capable of crossing the blood-brain barrier.
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
Denali will acquire the rights to bispecific antibodies targeting the blood-brain barrier that were developed under its collaboration with F-star.
With the new financing, Kallyope plans to move its pipeline programs toward the clinic and hire another 16 people.
Oncolytic viruses used in tandem with other treatments could be key for difficult-to-treat breast and brain cancers.
Lundbeck has struck a deal with Ossianix to use shark-derived antibodies to hustle drugs across the blood-brain barrier.